BioSpace News Archive

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced that members of the management team will present at the following investor conferences

Key Scientific Publication in Obstetrics & Gynecology Shows Sera is the Leading Authority in Assessing Preterm Birth Risk

ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and President, is an invited speaker at the Stifel 2019 Healthcare Conference

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate, WP1122, which it believes may present a new approach to treating highly glycolytic tumors like pancreatic cancer and glioblastoma.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company’s chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:40pm GMT.

Chilmark Research’s inaugural Healthcare Payer Analytics Market Trends Report confirms that the future of payer analytics is combined and aggregated clinical and claims datasets.

Partnership aims to engage citizen scientists and create a better understanding of debris and plastic pollution in coastlines and waterways through open data

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), the leading science-focused multi-state cannabis company, today announced that Amber Shimpa will be transitioning to the newly created role of Chief Administrative Officer (“CAO”) on December 2, 2019.

Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended September 30, 2019.

Evoke Pharma, Inc. (NASDAQ: EVOK), today announced that on November 12, 2019, it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has been granted an additional 180-day grace period to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2).